From Māngere To Medicine: Pacific Migrant Dreams Big
Article – Mary Afemata – Local Democracy Reporter
The scarcity of Pacific professionals in medicine empowers her, and she says visibility matters.
Māngere teen Selina Camillo, 18, migrated from Fiji to Māngere just a few years ago, but she's already making academic waves as she works towards becoming a heart surgeon.
Since setting foot in Aotearoa for the first time in December 2022, Camillo has topped her class, served as head girl at Southern Cross Campus, and is now studying at the University of Auckland – the first of her family to do so.
Studying a Bachelor of Biomedical Science, she is one of only 16 students awarded a Milford Foundation Scholarship this year, which provides up to $10,000 annually. She also received a University of Auckland Top Achiever Scholarship.
The funding has helped ease the cost pressure of studying, as she didn't want to be a financial burden for her parents, who secured permanent residency in January this year.
'I was always worried about how am I going to pay for my tuition fees,' she says.
'It really made me feel that it will bring me closer to achieving my dream of becoming a doctor.'
Her interest in the human heart stems back to a young age in Fiji and is what motivated her to specialise in cardiology.
'That was the first organ that I was taught in year 7 back home,' she says.
Camillo grew up seeing heart disease impact her family and other Pacific households, a pattern that school later confirmed was part of a global trend as one of the leading causes of death.
'So I was very interested in just being able to get into that field as a Pacifica to be able to help our people not only to treat the disease but also to help promote healthy lifestyle and bring a reduction to lives being affected by heart disease.'
Through her academic success, Camillo is proud to highlight her culture.
The scarcity of Pacific professionals in medicine empowers her, and she says visibility matters:
'So far I don't know any Rotuman doctor here nor my family, but there's only one Tuvaluan doctor I know who's based in Wellington,' she says.
'[Representation] is very important, especially coming from very small islands, Tuvalu and Rotuma. Most people don't even know where Rotuma is at all.'
Still, Camillo remains undeterred, her motivation is clear. 'I just want to be able to represent my island, my culture.'
Only 981 people in New Zealand identified as Rotuman and 4653 as Tuvaluan, according to the 2018 Census,
With small numbers, these groups are often lumped into the broader 'Other Pacific Peoples' category in education and government data, limiting their visibility and access to targeted resources.
Most assume she is Samoan, but she has to correct them by saying she's Rotuman or Tuvaluan – a culture many are unfamiliar with, she says.
'It helps people to know more about my people, my culture. So sometimes I feel proud of being able to put my culture somewhere that's good for others to see and also learn something new.'
She says her cultural upbringing shaped her values and her drive.
'Tuvaluan is my first language, mother tongue,' she says.
'Growing up with my grandparents and mum in Tuvalu, I learned a lot about my culture … we were just dependent on fishing and plantation.'
Also raised in Fiji, she learned to read using a Bible.
'My first book was the Bible because we couldn't really afford books. And by the end of Year 2, I also topped Year 2 in Fiji.'
She credits her grandparents' values – respect, humility, and discipline – with guiding her academic journey.
'I just wanted to be a role model to my siblings as I wanted to make a change in my family to make my parents proud in performing well in school.'
Milford Foundation CEO Bryce Marsden says the scholarship is about more than financial support.
'We've seen fantastic results from our first two cohorts. We look forward to the 2025 group joining them as future leaders and visionaries.'
This year, the Foundation has committed nearly $460,000 across three cohorts.
Camillo says her family is her 'why' and hopes to inspire others.
'Do not let your circumstances make you feel doubt about yourself or limit you from reaching your goals,' she says. 'Just grab every opportunity.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Scoop
a day ago
- Scoop
Clues To Diagnosing Parkinson's And MSA Discovered
Press Release – University of Auckland Australasian brain scientists have made a breakthrough that could help to diagnose Parkinson's disease and multiple system atrophy (MSA). Researchers at the University of Auckland's Centre for Brain Research – Dr Victor Dieriks and Dr James Wiseman – and University of Sydney Professor Glenda Halliday have discovered distinctive markers in the brains of people with the two diseases, which are often mistaken for one another in the early stages. 'It's vital to be able to accurately distinguish between Parkinson's and MSA early on, because this directly impacts on treatment decisions and patients' well-being,' says Dieriks. Currently, diagnosis of Parkinson's and MSA is based on patients' symptoms. Misdiagnosis often occurs, because the two conditions have similar symptoms. 'When misdiagnosed, patients with MSA are often given the Parkinson's drug, levodopa, which not only fails to help, but can worsen symptoms in some cases,' says Dieriks. While both conditions affect movement, Parkinson's typically progresses slowly with tremors, muscle stiffness, and slowness of movement. In contrast, MSA advances rapidly and includes problems such as severe balance issues, and disturbances in blood pressure and heart rate. The team used an innovative technique to study donated brain tissue in the Neurological Foundation Human Brain Bank in Auckland and the Sydney Brain Bank. They focused on a protein involved in both diseases – -synuclein – and found distinctive patterns and levels in Parkinson's, compared with MSA. 'We discovered this protein clumps differently in the brains of people with Parkinson's and MSA and the levels in MSA are far higher,' says Dieriks. Their discovery could pave the way for a simple, non-invasive test, such as a nasal swab, blood test, or urine sample, to reliably tell the two conditions apart. Lead researcher Wiseman says it's a significant breakthrough to be able to definitively diagnose Parkinson's and MSA from brain tissue. 'What's really exciting is we're a step closer to being able to diagnose these disorders by using readily available body fluids. 'This means we could pick up Parkinson's and MSA early, potentially before people even start to experience symptoms,' says Wiseman. Parkinson's disease affects millions globally, while MSA is far rarer, impacting about five in every 100,000 people. But MSA's toll is devastating, says Dieriks. 'MSA can turn active, independent people into individuals needing full-time care within just a few years. 'Whereas people with Parkinson's may live for decades, those with MSA typically survive only three to ten years after symptoms begin,' says Dieriks. Globally, research on Parkinson's is progressing rapidly, he says. 'We're closer than ever to developing a diagnostic test for Parkinson's. And the sooner we can catch these diseases, the better chance we have of slowing or stopping their progression.'
Scoop
a day ago
- Scoop
Clues To Diagnosing Parkinson's And MSA Discovered
Australasian brain scientists have made a breakthrough that could help to diagnose Parkinson's disease and multiple system atrophy (MSA). Researchers at the University of Auckland's Centre for Brain Research – Dr Victor Dieriks and Dr James Wiseman – and University of Sydney Professor Glenda Halliday have discovered distinctive markers in the brains of people with the two diseases, which are often mistaken for one another in the early stages. 'It's vital to be able to accurately distinguish between Parkinson's and MSA early on, because this directly impacts on treatment decisions and patients' well-being,' says Dieriks. Currently, diagnosis of Parkinson's and MSA is based on patients' symptoms. Misdiagnosis often occurs, because the two conditions have similar symptoms. 'When misdiagnosed, patients with MSA are often given the Parkinson's drug, levodopa, which not only fails to help, but can worsen symptoms in some cases,' says Dieriks. While both conditions affect movement, Parkinson's typically progresses slowly with tremors, muscle stiffness, and slowness of movement. In contrast, MSA advances rapidly and includes problems such as severe balance issues, and disturbances in blood pressure and heart rate. The team used an innovative technique to study donated brain tissue in the Neurological Foundation Human Brain Bank in Auckland and the Sydney Brain Bank. They focused on a protein involved in both diseases – -synuclein – and found distinctive patterns and levels in Parkinson's, compared with MSA. 'We discovered this protein clumps differently in the brains of people with Parkinson's and MSA and the levels in MSA are far higher,' says Dieriks. Their discovery could pave the way for a simple, non-invasive test, such as a nasal swab, blood test, or urine sample, to reliably tell the two conditions apart. Lead researcher Wiseman says it's a significant breakthrough to be able to definitively diagnose Parkinson's and MSA from brain tissue. 'What's really exciting is we're a step closer to being able to diagnose these disorders by using readily available body fluids. 'This means we could pick up Parkinson's and MSA early, potentially before people even start to experience symptoms,' says Wiseman. Parkinson's disease affects millions globally, while MSA is far rarer, impacting about five in every 100,000 people. But MSA's toll is devastating, says Dieriks. 'MSA can turn active, independent people into individuals needing full-time care within just a few years. 'Whereas people with Parkinson's may live for decades, those with MSA typically survive only three to ten years after symptoms begin,' says Dieriks. Globally, research on Parkinson's is progressing rapidly, he says. 'We're closer than ever to developing a diagnostic test for Parkinson's. And the sooner we can catch these diseases, the better chance we have of slowing or stopping their progression.'
Scoop
3 days ago
- Scoop
Womb Cancer 'Really Hitting The Pacific And Māori Communities', NZ Biologist Says
Christina Persico, RNZ Pacific Bulletin Editor Susana Suisuiki, Pacific Waves Presenter/Producer Christina Persico, RNZ Pacific Bulletin Editor A University of Auckland biologist working on less invasive tests for womb cancer (or endometrial cancer) says studies suggest that one of its causes is higher weight or metabolic diseases, such as diabetes. The number of diagnoses of the disease in New Zealand has risen from 600 a decade ago to around 750 a year. Māori and Pasifika women have some of the highest rates of womb cancer in the world. Researchers say younger New Zealand women are now being diagnosed with womb cancer, which previously struck after menopause. It is occurring in women aged 30 to 40 and is particularly prevalent in Māori and Pasifika populations. "We need to do a bit more work and to have a look at the numbers," Dr Cherie Blenkiron told Pacific Waves. "But the studies that are out there suggest that is really one of the main in New Zealand, for the increased number of people who are being diagnosed each year. "Unfortunately, that really is hitting the Pacific and Māori communities." She said there have been "really tight studies" that have shown that one of the causes is higher weight or metabolic diseases, such as diabetes. "What they've shown in these trials overseas is if you treat and you manage those conditions better, then you reduce the likelihood of those women developing endometrial cancer." However, Dr Blenkiron said it is a type of cancer that can be removed if found early. Symptoms can include cramping and abnormal bleeding or spotting. "You know your body perfectly well, so if there's any change in in bleeding, then really do get it checked out by your GP. "Women will present with symptoms, and that really means that if they act on those can pick up the cancer early, we can treat it early, and this is a type of cancer that can be cured very easily with surgery or really limited forms of drugs." The new screening tests the university is working on aim to do move away from "quite nasty" biopsies and to minimally invasive tests, Dr Blenkiron said. "We're looking for molecules, for example, in the blood or in little biopsies. Or one of the projects that we're doing is looking for swabs. So taking self swabs, much like have been done in cervical cancer," she said. "So blood tests, swab tests - much easier to take and much more painless. "What we do with these tests is to first, hopefully, pick up the cancer earlier. So these would be screening tests. "And second to pick the right medicine or the right treatment for each patient," she added.
